ProMIS Neurosciences Inc at HC Wainwright Investment Conference - New York Transcript
Hi, good afternoon, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Ananda Ghosh, an associate at H.C. Wainwright. That said, I would like to welcome Gail Farfel, CEO of ProMIS Neurosciences; and Larry Altstiel, CMO of ProMIS Neurosciences.
Thank you.
Thank you, Anand. It's a pleasure to be here, and we thank the organizers for inviting us. My disclosures -- or our disclosures are contained here. ProMIS Neurosciences is a company developing next-generation antibodies for treatment of neurodegenerative diseases. We have a proprietary platform, a computational algorithm that allows us to predict how proteins can misfold and then design antibodies -- generate antibodies specific to toxic misfolded forms of these proteins.
Our lead compound, our lead candidate is PMN310,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |